[Anti- XXXX monoclonal antibodies (infliximab) and @entity378 : apropos of 3 cases].

@entity1 @entity310 @entity9178 @entity166 @entity1292 @entity378 @entity221 @entity309 @entity1907
INTRODUCTION: Monoclonal @entity310 antibodies are a new treatment of severe @entity309 . One of the possible side effects is the appearance of @entity1292 . We report here on three cases of disseminated @entity378 observed in @entity1 undergoing treatment with infliximab. EXEGESIS: A 45-year-old @entity1 , treated with infliximab, was hospitalised after five infusions for @entity221 and dyspnoea. The exams showed @entity1907 . The second case is a 75-year-old @entity1 whose symptoms were @entity221 , cough and cervical adenopathy after three infliximab infusions. Diagnosis was disseminated @entity378 . The third case is a 59-year-old @entity1 who was hospitalised for an @entity166 with dyspnoea, after two infliximab infusions. We discovered @entity1907 . CONCLUSION: These three cases added to the 68 cases of @entity378 registered with the treatment of infliximab. This confirms the risk of severe opportunist infectious side effects. @entity310 is a cytokine which has anti-infectious properties. These @entity378 are severe and generalized. It is recommended to search for an active or @entity9178 before beginning treatment with infliximab, and to check these @entity1 frequently.
